Date:11/3/2008

cts; our ability to transition our management teams effectively; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Critical Therapeutics' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as amended, filed with the SEC and other SEC filings, including, but not limited to, those set forth in the section entitled "Risks Related to Cornerstone" beginning on page 59 of the proxy statement/prospectus Critical Therapeutics filed with the SEC pursuant to Rule 424(b)(3) on October 6, 2008, and in other filings that Cornerstone Therapeutics makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We a
'/>"/>

SOURCE Cornerstone BioPharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
6. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
9. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development